Registered number
SC760759
Adeel Ahmed Pharm Ltd
Filleted Accounts
31 March 2024
Adeel Ahmed Pharm Ltd
Registered number: SC760759
Balance Sheet
as at 31 March 2024
Notes 2024
£
Fixed assets
Tangible assets 3 1,780
Current assets
Cash at bank and in hand 5,342
Creditors: amounts falling due within one year 4 (5,641)
Net current liabilities (299)
Net assets 1,481
Capital and reserves
Called up share capital 100
Profit and loss account 1,381
Shareholders' funds 1,481
The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Adeel Ahmed
Director
Approved by the board on 18 November 2024
Adeel Ahmed Pharm Ltd
Notes to the Accounts
for the period from 2 March 2023 to 31 March 2024
1 Accounting policies
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Fixtures, fittings, tools and equipment 20% reducing balance
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods.
2 Employees 2024
Number
Average number of persons employed by the company 2
3 Tangible fixed assets
Plant and machinery etc
£
Cost
Additions 2,225
At 31 March 2024 2,225
Depreciation
Charge for the period 445
At 31 March 2024 445
Net book value
At 31 March 2024 1,780
4 Creditors: amounts falling due within one year 2024
£
Taxation and social security costs 4,892
Other creditors 749
5,641
5 Controlling party
Mr Adeel Ahmed is the ultimate controlling party.
6 Other information
Adeel Ahmed Pharm Ltd is a private company limited by shares and incorporated in England. Its registered office is:
64 Raeswood Crescent
Glasgow
Scotland
G53 7HE
Adeel Ahmed Pharm Ltd SC760759 false 2023-03-02 2024-03-31 2024-03-31 VT Final Accounts April 2024 Adeel Ahmed No description of principal activity SC760759 2023-03-02 2024-03-31 SC760759 bus:PrivateLimitedCompanyLtd 2023-03-02 2024-03-31 SC760759 bus:AuditExempt-NoAccountantsReport 2023-03-02 2024-03-31 SC760759 bus:Director40 2023-03-02 2024-03-31 SC760759 1 2023-03-02 2024-03-31 SC760759 2 2023-03-02 2024-03-31 SC760759 countries:England 2023-03-02 2024-03-31 SC760759 bus:FRS102 2023-03-02 2024-03-31 SC760759 bus:FilletedAccounts 2023-03-02 2024-03-31 SC760759 2024-03-31 SC760759 core:WithinOneYear 2024-03-31 SC760759 core:ShareCapital 2024-03-31 SC760759 core:RetainedEarningsAccumulatedLosses 2024-03-31 SC760759 2023-03-01 iso4217:GBP xbrli:pure